Ocular Therapeutix Inc (OCUL) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
Ocular Therapeutix Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period
Return on Investment, Quarterly Results, Trends, Rankings, Statistics
What is Ocular Therapeutix Inc's ROI in the second quarter of 2026?
Ocular Therapeutix Inc recorded a cumulative net loss of $-301 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -49.53%.
Within the Healthcare sector 469 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Jun 30 2026 quarter, so far to 3751, from total ROI ranking in the first quarter of 2026 at 4403.
Ocular Therapeutix Accelerates Wet AMD Trials Amid Strategic Expansion and Legal Expertise EnhancementsIn the dynamic landscape of biopharmaceutical innovation, Ocular Therapeutix, Inc. (NASDAQ: OCUL) has taken decisive steps towards solidifying its status as a pioneering leader in developing transformative therapies for retinal diseases and ocular conditions. Based in Bedford, Massachusetts, the company is increasingly making
Ocular Therapeutix Inc, a leading biopharmaceutical company specializing in innovative eye therapies, recently announced significant additions to its clinical team. This strategic move aims to strengthen the company s medical expertise and propel its research and development efforts forward. Nadia K. Waheed, MD, MPH, has been appointed as the Chief Medical Officer, while Peter K. Kaiser, MD, will assume the role of Chief Development Officer. Additionally, Andrea Gibson, PhD, has been named Vice President of Medical Collaborations, and Namrata Saroj, OD, joins as the Development Strategy Consultant. This article delves into the implications of these appointments and analyzes their potential impact on Ocular Therapeutix s future prospects, considering the company s recent financial challenges.
Ocular Therapeutix Inc has made a strategic move to fortify its clinical team with the inclusion of renowned retinal experts. These appointments represent a strategic effort by the company to leverage their expertise in advancing its product pipeline and addressing previously reported financial challenges. The new additions are expected to augment the company s clinical capabilities and pave the way for the development of breakthrough eye therapies.
In a recent announcement, Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on developing and commercializing innovative therapies for eye-related diseases, revealed that it has granted inducement equity awards to its newly appointed Senior Vice President, Global Head of Biometrics, Liansheng Zhu. These awards were approved by Ocular s Compensation Committee and were offered to Dr. Zhu as an incentive for joining the company. Ocular Therapeutix is committed to improving people s vision and quality of life by creating treatments for conditions such as wet age-related macular degeneration (wet AMD) and diabetic retinopathy. The company aims to bring innovative therapies to market that address the unmet medical needs of patients with eye-related diseases.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
